Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
Founders’ story: Pleiogenix
01:30pm, Tuesday, 18'th Aug 2020
Pleiogenix is a biopharma startup developing treatments for liver diseases as well as Covid-19 and non-alcoholic steatohepatitis (NASH). It recently emerged as the winner of the INVEST Pitch Perfect
Viking Therapeutics: Another Year In Review
02:39pm, Thursday, 13'th Aug 2020
Recently announced Q2'20 financial results and provided key updates on development timelines. Filed IND for VK0214 in X-ALD.
Akero Therapeutics Reports Second Quarter 2020 Financial Results
08:05pm, Wednesday, 12'th Aug 2020
Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall h
CymaBay Therapeutics Inc. (CBAY) Q2 2020 Earnings Call Transcript | The Motley Fool
07:01am, Tuesday, 11'th Aug 2020
CBAY earnings call for the period ending June 30, 2020.
How Adam Smith Might Have Valued Amazon, Netflix, Tesla, And Tiny Biotechs (NASDAQ:AMZN)
04:23pm, Monday, 10'th Aug 2020
Adam Smith's invisible hand implies that the value a business provides to its customers is conjoined with the value of a business to its self-interested owners.
Inventiva S A : Descriptif du programme limité de rachat d'actions & reprise du contrat de liquidité | Zone bourse
03:54pm, Monday, 10'th Aug 2020Inventiva S A : DESCRIPTIF DU PROGRAMME LIMITE DE RACHAT D'ACTIONS & REPRISE DU CONTRAT DE LIQUIDITE | Zone bourse
03:45pm, Monday, 10'th Aug 2020
Terns Pharmaceuticals Appoints Senthil Sundaram as CEO, Mark Vignola, Ph.D., as CFO, and Erin Quirk, M.D., as President.
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2020 Results - Earnings Call Transcript
05:23pm, Sunday, 09'th Aug 2020
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Q2 2020 Results Conference Call August 06, 2020 08:30 AM ET Company Participants Allen Baharaff - President and CEO Dr.
Alnylam Managing Through Covid-19 Challenges And Executing Well (NASDAQ:ALNY)
04:34pm, Friday, 07'th Aug 2020
COVID-19 drove a double-digit sequential decline in U.S. Onpattro revenue, but both Onpattro and Givlaari revenue exceeded expectations, with management lifting the lower end of its Onpattro revenue f
Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jorgensen on Q2 2020 Results - Earnings Call Transcript
09:32am, Friday, 07'th Aug 2020
Novo Nordisk A/S (NYSE:NVO) Q2 2020 Earnings Conference Call August 6, 2020 07:00 ET Company Participants Lars Fruergaard Jorgensen - Chief Executive Officer Mads Krogsgaard Thomsen - EVP & Chief
Amarin Earnings, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:AMRN)
09:11pm, Thursday, 06'th Aug 2020
Amarin reports better than expected financial numbers for second quarter. CytoDyn reports positive DSMC opinion for COVID-19 trial.
Fractyl Raises $55 Million in Series E Financing to Advance Revita DMR for Type 2 Diabetes
12:00am, Thursday, 06'th Aug 2020
Fractyl's first close of $55 million will be used to support the Revita T2Di pivotal US clinical trial of Revita DMR to treat type 2 diabetes.
Merck & Co to repurpose failed obesity drug for NASH -
07:21am, Wednesday, 05'th Aug 2020
Merck & Co is to pay $10 million to Hanmi to repurpose a drug discarded by Johnson & Johnson in obesity into a therapy for the fatty liver disease also known as NASH.
GENFIT : la technologie NIS4 objet d'une publication dans The Lancet Gastroenterology
07:20am, Wednesday, 05'th Aug 2020
(AOF) - Genfit annonce que les données décrivant la dérivation et la validation de NIS4 ont été acceptées pour publication dans The Lancet Gastroenterology & Hepatology. NIS4 est la technologie
